Posted by Michael Wonder on 11 Jul 2023
Synlogic granted fast track designation from FDA for labafenogene marselecobac (SYNB1934) for treatment of phenylketonuria
11 July 2023 - Synlogic today announced that the US FDA has granted fast track designation to labafenogene marselecobac (previously known as SYNB1934) for the treatment of phenylketonuria.
Labafenogene marselecobac has also received rare disease designation and orphan drug designation by the FDA and orphan designation from the EMA.
